Once a candidate has good PD (it hits the target) and good PK (it stays in the body long enough), it moves to preclinical testing. Here, pharmacology merges with toxicology.
Drug discovery begins with a disease hypothesis. Pharmacology steps in to validate the biological target—typically a receptor, enzyme, ion channel, or nucleic acid. Using tools like CRISPR-Cas9, RNA interference, and monoclonal antibodies, pharmacologists confirm that modulating this target will indeed produce a therapeutic effect.
For example, in the discovery of statins (HMG-CoA reductase inhibitors), pharmacological validation proved that inhibiting this liver enzyme directly lowered LDL cholesterol. Without this proof, investment in chemical synthesis would be gambling, not science. pharmacology in drug discovery and development
Pharmacology is not a single step in drug discovery—it is an iterative, omnipresent discipline. It begins with the question “Which target will modify disease?” and continues through every dose decision in a patient’s life. A drug without a strong pharmacological foundation is like a ship without a rudder: it might move, but not in a predictable or safe direction. Mastery of PK/PD principles is the single most effective way to reduce attrition and bring better medicines to patients faster.
“The right drug, at the right dose, for the right patient” — pharmacology is the science that makes this possible. Once a candidate has good PD (it hits
Is the target relevant in a living, breathing system? Pharmacologists use animal models of disease:
Success here is not guarantee of human success (the "translational gap"), but failure here is a definitive stop. “The right drug, at the right dose, for
In 2006, this CD28 superagonist caused catastrophic multi-organ failure in six healthy volunteers within hours. The failure was pharmacological in vitro-to-in vivo translation. Preclinical studies in cynomolgus monkeys used a different CD28 expression profile on T-cells. Human T-cells were hyper-responsive. Outcome: New era of in vitro human cell-based assays (e.g., using human peripheral blood mononuclear cells) before FIH trials.
In the popular imagination, drug discovery is often viewed as a moment of sudden inspiration—a "Eureka!" instant where a scientist stumbles upon a cure. In reality, it is a grueling, high-stakes marathon characterized by high attrition rates and soaring costs. At the heart of this complex odyssey lies pharmacology: the science of how drugs interact with living organisms.
Pharmacology serves as the bridge between chemistry and medicine. It is the discipline that transforms a chemical entity found in a test tube into a safe, effective medicine suitable for a human patient. Without pharmacology, the drug development pipeline would be a directionless accumulation of molecules.